1 AlloMap results were considered High for scores >30 (<6 months post-transplant) or >34. AlloSure Heart results were considered High for 0.2% dd-cfDNA or greater. Data are a combination of CARGO II and DOAR outcomes CARGO II and DOAR. Unpublished raw data. Endpoints measured were rejection episodes.
2 Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-Expression Profiling for Rejection Surveillance after Cardiac Transplantation. New England Journal of Medicine 2010;20:1890–1900.
3 Crespo-Leiro MG, et al. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J. 2016; 37(33):2591-601
4 Crespo-Leiro MG, et al. Abstract of “Increased Plasma Levels of Donor-Derived Cell-Free DNA Correlate With Rejection in Heart Transplant Recipients: The CARGO II Multicenter Trial.” International Society for Heart and Lung Transplantation (ISHLT), 35th Annual Meeting and Scientific Sessions April 15 – 18, 2015. Nice, France.
*AlloMap Molecular Expression Testing is an In Vitro Diagnostic Multivariate Index assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment.